Kornimate/medical-research-clean huggingface dataset:
reliability of simple sonographic findings acquired with hand-held apparatuses to inform obstetric diagnosis

Conditions: Obstetric Complication; Vaginal Bleeding; Eclampsia Preeclampsia; Obstructed Labor; Antepartum Hemorrhage

Summary: the study aims to assess the reliability of ultrasound findings measured by hand held ultrasound probes used by operators with variable experience in a low resource hospital.

rationale: the majority of obstetric emergencies are identified through clinical examination, which cannot be substituted by ultrasound. however, just as a laboratory exam, ultrasonograpy can provide swift point of care information on fetus presentation, viability, placenta position, quantity of amniotic fluid and presence of abdominal fluid to inform the clinical reasoning and therapeutic escalation. ultrasound literature in low-resource settings has favoured antenatal care (anc) rather than the emergency setting. also, hand-held ultrasound machines may not be as performant as traditional machines used by expert operators but to date is still to be tested in a low resource setting. objective: to assess the reliability of ultrasound findings measured by hand held ultrasound probes used by operators with variable experience in a low resource hospital. hypothesis: there is substantial agreement between simple ultrasound findings identified using hand held ultrasound devices and the reference standard. study design: a prospective observational diagnostic accuracy study. study population: parturients admitted to the princess christian maternity hospital (pcmh) in freetown, sierra leone. sample size: no formal sample size calculation is performed. based on current rates of admissions to the pcmh we expect to perform obstetrical ultrasound scan in at least 300 patients during a 2-months study period. methods: 4 trained physicians (3 naive and 1 intermediate ultrasound users) will perform the ultrasound investigations using the hand held device and complete a structured predefined report form of obstetric ultrasound findings at patient admission or according to clinical indications after admission. these will be compared with the reference standard, i.e. an ultrasound examination performed by a specialist gynecologist/obstetrician using a conventional apparatus in the hospital ultrasound room. main study parameters/primary endpoints: the mean diagnostic accuracy among nine ultrasound obstetric findings collected with hand held devices versus the reference standard.

Eligibility criteria:
inclusion criteria: * admitted to the emergency department, outpatient department, in-patient department or antenatal care (anc) of the pcmh during the study period. * fulfills one or more of the five inclusion categories: i.e. vaginal bleeding in early pregnancy, pre-eclampsia, prolonged/obstructed labor, antepartum hemorrhage (aph) and other high risk pregnancies encountered in anc. exclusion criteria: * ultrasound examination not feasible, e.g., due to electricity breakdown, or physical absence or unavailability of the trained sonographers.
utilization of motor imagery training for improvement of balance of ataxic children after medulloblastoma resection

Conditions: Cerebellar Ataxia

Summary: background: after resection of medulloblastoma in children they suffer from signs and symptoms of ataxia which impedes their activities of daily living. purpose: to investigate the effect motor imagery training on balance, severity of ataxia and gait parameters on children after resection of medulloblastoma. methods: fifty children surfing from cerebellar ataxia after medulloblastoma resection were selected from tumors hospital of cairo university, their age ranged from seven to nine years old, they were randomly assigned into two matched control and study groups. the control groups received the selected physical therapy program while, the study group received motor imaginary training in addition to the selected physical therapy program. both groups were evaluated by ataxic rating scale, pediatric berg balance scale and kinematic gait analysis by kinovea software.

motor imagery is an effective method to enhance motor performance applied in rehabilitation programs it did not impose a physical load on patients, was confirmed through clinical evidence from meta#analysis. motor imagery means thinking in motor task with executing it to activate motor cortical areas as 25% of the brain neurons are mirror neurons and fire by thinking.

Eligibility criteria:
inclusion criteria: * the children had signs of ataxia * loss of balance * able to understand and execute test instructions * the children are in the follow up period after medulloblastoma resection exclusion criteria: * medically unstable * visual impairment * increased intracranial pressure * any other neuromuscular diseases.
study of immunotherapy combined with chemotherapy in locally advanced and metastatic pancreatic cancer

Conditions: Locally Advanced and Metastatic Pancreatic Cancer

Summary: to evaluate the efficacy of pd-l1/ctla4 bsab for the second line treatment and the combination with chemotherapy for the first line treatment in pancreatic cancer

subjects who signed the informed consent were assigned to three cohorts according to the actual treatment status. cohort 1 enrolled subjects receiving pd-l1/ctla4 bsab 5mg/kg iv q2w for 2nd treatment; cohort 2 enrolled subjects receiving pd-l1/ctla4 bsab in combination with gemcitabine/albumin- paclitaxel as 1st treatment for 4-6 cycles with pd-l1/ctla4 bsab monotherapy maintainence; cohort 3 enrolled subjects received systemic chemotherapy, receiving pd-l1/ctla4 bsab combined with oxaliplatin / irinotecan / leucovorin / fluorouracil (folfirinox) as 1st treatment for 4-6 cycles withpd-l1/ctla4 bsab monotherapy maintainence; until disease progression according to recist 1.1, intolerable toxicity, withdrawal, death, 2-yr treatment,who comes first.

Eligibility criteria:
inclusion criteria: * histology or cytology confirmed as pancreatic ductal adenocarcinoma; * ecog 0-1; * adequate organ function (absolute neutrophil count ≥1.5 x 109/l; platelet count ≥100 x 109/l; creatinine \< 1.5 x uln (upper normal) or calculated creatinine clearance ( crci) ≥ 60ml/min; albumin ≥ 30g/l; total bilirubin \<1.5 x uln; aspartate aminotransferase (ast) \< 2.5 x uln; alanine aminotransferase (alt) \< 2.5x uln; inr or pt \< 1.5x uln, and aptt \<1.5x uln); * no obvious symptoms of jaundice and ascites; * no other serious underlying diseases exclusion criteria: * patients with active brain metastases; * history of autoimmune diseases, or need to be treated with corticosteroids and immunosuppressive agents; * past history of unstable angina, symptomatic congestive heart failure, severe arrhythmia, myocardial infarction within 6 months, qt interval prolongation (\>450ms); * other malignant tumors within the last 5 years; * pregnant or lactating women; * nrs ≥ 4 points; * unintentional weight loss ≥ 5% within 1 month before the first dose even if peripheral or central vein nutrition support,
a study of cle-400 (topical gel) for the treatment of chronic pruritus in adult subjects with notalgia paresthetica

Conditions: Chronic Pruritus in Adult Subjects with Notalgia Paresthetica (NP)

Summary: this is a phase 2, randomized, double-blind, vehicle-controlled study to assess the efficacy and safety of cle-400 topical gel for the treatment of chronic pruritus in adult subjects with notalgia paresthetica (np).

study to assess the efficacy and safety of cle-400 topical gel applied once daily for the treatment of moderate-severe chronic pruritus in adult subjects with np. the study comprises a screening phase of up to 37 days, including a 7-day run-in period, a 4-week double-blind treatment period, and a 2-week follow-up period.

Eligibility criteria:
inclusion criteria: * subject has a confirmed diagnosis of notalgia paresthetica. * subject has a history of chronic pruritus (itch) due to notalgia paresthetica. * subject has moderate to severe pruritus. * subject is able and competent to read and sign the informed consent form (icf). exclusion criteria: * subject has chronic pruritus that is related to a condition other than notalgia paresthetica. * subject with known or suspected history of a clinically significant systemic disease, unstable medical disorders, life-threatening disease, including physical/laboratory/ecg/vital signs abnormality that would put the subject at undue risk or interfere with interpretation of study results * subject is a female who is breastfeeding, pregnant, or who is planning to become pregnant during the study.
ultrasonographic parameters and life quality in nocturnal shoulder pain

Conditions: Musculoskeletal Pain

Summary: this study aimed to investigate the effects of nocturnal pain on clinical and ultrasonographic parameters in patients with rotator cuff tendinopathy.

thirty patients with nocturnal pain, 30 patients without nocturnal pain, and 30 healthy subjects were included in the study. the demographic characteristics and body mass indexes of the patients were recorded. the visual analogue scale was used to determine pain severity. the american shoulder and elbow surgeons scale assessment, short form-36 and beck depression inventory were used to determine patients' shoulder function, general quality of life and depression levels, respectively. the peak systolic velocity and resistive index of anterior circumflex humeral artery was assessed with power doppler ultrasonography.the peak systolic velocity and resistive index of anterior circumflex humeral artery values of the affected and unaffected sides were compared.

Eligibility criteria:
inclusion criteria: * patients aged over 18 years diagnosed with rotator cuff tendinopathy exclusion criteria: * severe limitation and pain in head and neck movements * loss of strength * sensation and reflexes loss in the upper extremity * limitation in passive shoulder movements on physical examination * systemic rheumatic disease * diabetes mellitus * malignant disease * active infection * intraarticular injection * trauma * dementia * history of surgery * bilateral should pain * psychiatric discomfort * smoking history * antiinflammatory drugs or received physical therapy within the last 3 months * beck depression score of higher than 13.

Keywords: nocturnal pain shoulder pain ultrasonography resistive index quality of life anterior circumflex humeral artery
a study to test if fremanezumab is effective in preventing chronic migraine in patients 6 to 17 years of age

Conditions: Migraine

Summary: the primary objective of the study is to evaluate the effectiveness of fremanezumab as compared to placebo for the preventive treatment of chronic migraine (cm). secondary objectives are to further demonstrate the efficacy of fremanezumab as compared to placebo for the preventive treatment of cm, to evaluate the safety and tolerability of fremanezumab in the preventive treatment of cm and to evaluate the immunogenicity of fremanezumab and the impact of antidrug antibodies (adas) on clinical outcomes in participants exposed to fremanezumab the total duration of the study is planned to be 75 months.


Eligibility criteria:
inclusion criteria: * the participant has a clinical history of recurrent headache consistent with the diagnosis of migraine for at least 6 months before screening, consistent with ichd-3 criteria (headache classification committee of the ihs 2013), and a history of ≥15 headache days per month on average during the 3 months prior to screening (visit 1). * the participant or parent/caregiver maintain a prospectively collected headache diary note: additional criteria apply; please contact the investigator for more information. exclusion criteria: * the participant is using medications containing opioids (including codeine) or barbiturates (including fiorinal®, fioricet®, or any other combination containing butalbital) for the treatment of migraine during the 3 months prior to the day of the screening visit. * the participant has used an intervention/device (eg, scheduled nerve block or transcranial magnetic stimulation) for the treatment of migraine or in the head or neck area for any condition during the 2 months prior to the day of the screening visit. * the participant has a current history of a clinically significant psychiatric condition, at the discretion of the investigator. any prior history of a suicide attempt, or a history of suicidal ideation with a specific plan within the past 2 years must be excluded. * the participant has an ongoing infection or a known history of human immunodeficiency virus infection, tuberculosis, lyme disease, or chronic hepatitis b or c, or a known active infection of coronavirus disease 2019 (covid-19). * the participant has a past or current history of cancer. * the participant is pregnant or nursing. * the participant has a history of hypersensitivity reactions to injected proteins, including mabs, or a history of stevens-johnson syndrome or toxic epidermal necrolysis syndrome, or the participant is concomitantly using lamotrigine. * the participant received a live attenuated vaccine (eg, intranasal flu vaccine, and measles, mumps, and rubella vaccine) within the 12-week period prior to screening. note: if a medical need arises during the study, the participant may receive a live attenuated vaccine. * the patient has a current or past medical history of hemiplegic migraine. note: additional criteria apply; please contact the investigator for more information.
pimecrolimus cream 1% in patients (18 years of age and over) with mild to moderate chronic hand dermatitis

Conditions: Chronic Hand Dermatitis

Summary: topical steroids are standard of care for chronic hand dermatitis, but long-term use is associated with adverse effects. this study will assess the efficacy and safety of pimecrolimus cream 1% in patients with mild-to-moderate chronic hand dermatitis.


Eligibility criteria:
inclusion criteria: * - patients who are outpatients at baseline (day 1) * patients must be 18 years of age or above * patients must have chronic hand dermatitis based upon clinical diagnosis with mild to moderate dermatitis of the target hand at baseline, as defined by an investigator's global assessment score of 2 (mild) or 3 (moderate). * patients must have been informed of the study procedures and medication and have given their written informed consent exclusion criteria: * - women who are pregnant or who are breast-feeding. * patients who have received systemic corticosteroids (i.e., oral, intravenous, intra-articular, rectal, intramuscular) within one month prior to first application of study medication. * patients who have received phototherapy (e.g., uvb, puva) or systemic therapy (e.g., immunosuppressants, cytostatics) known or suspected to have an effect on hand dermatitis within at least one month prior to first application of study medication. * patients who have received pimecrolimus cream 1% or tacrolimus ointment 0.1% or 0.03% within 14 days prior to first application of study medication. * patients who were treated with topical therapy (e.g., tar, topical corticosteroids, burrows solution soaks) known or suspected to have an effect on hand dermatitis within 7 days prior to first application of trial medication. other protocol-defined inclusion/exclusion criteria may apply.

Keywords: chronic hand dermatitis, pimecrolimus, dermatitis
a database survey of comparison the risk of haemorrhage between vortioxetine tablet treatment and selective serotonin reuptake inhibitor (ssri) treatment in participants with depression

Conditions: Major Depressive Disorder

Summary: this study is a retrospective database study in japan to evaluate the relative risk of serious intracranial hemorrhage requiring hospitalization between vortioxetine tablet treatment and selective serotonin reuptake inhibitor (ssri) treatment for patients with depression. this survey will conduct in use of medical database called jmdc claims database.


Eligibility criteria:
inclusion criteria: 1. has diagnosis of depression and prescription of vortioxetine tablet or ssri within the enrollment period (index date: first prescription date within the enrollment period). 2. participants can be observed for the past 6 months (180 days) (look back period) from the day before the index date. 3. had not prescription of vortioxetine tablet or ssri in the look back period. exclusion criteria: 1. has diagnosis of intracranial hemorrhage during the look back period. 2. has been taken vortioxetine tablet in combination with ssri on the index date.
evaluation of the safety of lipiodolⓡ embolization in symptomatic digital osteoarthritis refractory to conventional treatment

Conditions: Osteoarthritis

Summary: the goal of this clinical trial is to evaluate the safety of arterial embolization using lipiodol® in patients with symptomatic hand osteoarthritis refractory to conventional treatment. it will also learn about the efficacy of arterial embolization with lipiodol® in reducing pain and improving hand function. the main questions it aims to answer are: * what are the side effects and complications associated with the lipiodol® arterial embolization procedure? * does arterial embolization reduce pain intensity and improve hand function? researchers will evaluate patients over a 6-month period to assess the safety of lipiodol® embolization and its impact on joint pain, swelling, and functional capacity. participants will: * undergo arterial embolization with lipiodol® * participate in regular follow-ups to monitor pain relief, hand function, and any side effects * have imaging studies to assess changes in joint vascularisation and damage


Eligibility criteria:
inclusion criteria: * patients aged ≥ 40 years. * osteoarthritis of the hand according to american college of rheumatology criteria 1990 * osteoarthritis affecting at least two proximal and/or distal interphalangeal joints with a radiological kellgren-lawrence stage ≥ 2. * symptomatic osteoarthritis within the last 3 months. * visual analogue pain scale of the hand to be treated ≥ 40/100 mm (most painful hand). * inadequate response, adverse effects and/or contraindication to nsaids and non-opioid analgesics. * patient affiliated to french social security or a similar health assurance. exclusion criteria: * history of allergy to iodinated contrast media, lipiodolⓡ or poppies. * vasomotor disorders (raynaud\&#39;s syndrome, scleroderma, acrocyanosis). * stenosis (\&gt;50%) or known atheromatous arterial occlusion of the upper limbs. * obliterative arterial disease of the lower limbs at the critical ischaemia stage. * severe to end-stage chronic renal insufficiency (glomerular filtration rate \&lt; 30ml/min/1.73m2), dialysis or renal transplant. * arteritis such as thromboangiitis obliterans disease or other diseases * previous thrombosis/dissection of the radial artery. * chronic inflammatory rheumatic disease (rheumatoid arthritis, psoriatic arthritis, microcrystalline arthritis, etc.). * known hyperthyroidism or large multinodular goiter. * traumatic lesions, haemorrhages or chronic bleeding in the hand (not completely resolved within 3 months of the start of the lesion) requiring embolisation. * pregnant or breast-feeding. * patients covered by articles l1121-5 to l1121-8 of the french public health code and/or who do not speak french. * patients in a period of exclusion or in the course of another interventional clinical trial.

Keywords: therapeutic embolization safety hand osteoarthritis
nlr and plr levels following ipack block in hip arthroplasty

Conditions: Hip Arthropathy; Hip Osteoarthritis; Hip Pain Chronic

Summary: effect of peng block on nlr and plr following hip arthroplasty

the nlr is a sensitive indicator of inflammation confirmed in numerous studies and has a predictive and prognostic value. nlr is a cheap, simple, fast-acting, readily available stress and inflammation parameter with high sensitivity and low specificity. dynamic changes in the nlr precede the clinical state by several hours and may alert clinicians to the ongoing pathological process early. nlr is a new promising marker of cellular immune activation, an important indicator of stress and systemic inflammation. it opens a new dimension for clinical medicine, enabling a better understanding of the biology of inflammation, the linkage and antagonism between innate and adaptive immunity, and their clinical consequences for health and disease. nlr is affected not only by surgical trauma but also by the method of anesthesia. in recent years, the influence of regional anesthesiology on reducing the inflammatory response after surgical procedures has been emphasized. however, there have been very few studies evaluating the effect of various methods of anesthesia on the nlr.

Eligibility criteria:
inclusion criteria: * patients with asa classification i-iii * aged 20-90 years * who will be scheduled for hip arthroplasty under spinal anesthesia exclusion criteria: * patients who have a history of bleeding diathesis * take anticoagulant therapy * history of chronic pain before surgery * multiple trauma * patients unable to assess their pain (dementia) * patients operated under general anesthesia * patients having an infection in the region of the procedure * the patient who does not accept the procedure